CD-MEDICS

The overall concept of the CD-MEDICS IP is to develop a technology platform for point-of-care diagnostics, capable of simultaneous genomic and proteomic detection, with embedded communication abilities for direct interfacing with hospital information systems. This will be achieved by exploiting breakthroughs at the confluences of bio-, micro- and nano- technologies to create a low-cost non-invasive intelligent diagnosis system.

This platform will be developed in a modular format, which will allow each module to be developed and exploited individually. The modules will subsequently be integrated to facilitate the desired application. Advances in data communications, molecular biology and biosensor technology, with the integration of nanostructured functional components in macro and microsystems, will facilitate the realisation of a minimally invasive generic platform, which is capable of multi-parametric monitoring and will be interoperable with electronic medical records.

The advantages of integrated biosensor systems include their ease of use, their sensitivity, their inherent selectivity (preventing problems due to interfering substances), their versatility (allowing `in-field¿ use) and their cost effectiveness. Addressing the future health care requirement of an individualised theranostic approach, the specific application that will be demonstrated in this IP will be for the management, monitoring and diagnosis of coeliac disease, with the proposed technology contributing to significant advances in sensitivity and specificity of diagnosis. The technology platform developed, however, could be applied to a variety of clinical screening applications, such as cancer. The radical innovation proposed in this IP will result in a concrete prime deliverable of a technology platform of wide application and unquestionable socio-economic benefit, increasing European competitiveness whilst contributing considerably to the quality of life well being of the population.

For further information, please visit:
http://www.cdmedics.eu

Project co-ordinator:
Universitat Rovira i Virgili

Partners:

  • Institut für Mikrotechnik Mainz GmbH
  • Microfluidic ChipShop GmbH
  • Newcastle University
  • Intracom Telecom solutions
  • Clemens GmbH
  • Micro2Gen
  • Eurospital SpA
  • King's College London Business Ltd
  • INNO-TRAIN Diagnostik GmbH
  • TATAA Biocenter
  • MultiD Analyses AB
  • Finnish Red Cross Blood Service
  • Fondazione IRCCS Policlinico San Matteo
  • University Medical Centre Maribor
  • Valentia Technologies Limited
  • Association of European Coeliac Societies
  • Coeliac UK
  • Asociación de celíacos de Madrid
  • iXscient Ltd.
  • Newcastle upon Tyne Hospitals NHS Foundation Trust

Timetable: from 01/2008 – to 12/2011

Total cost: € 12.796.559

EC funding: € 9.500.000

Programme Acronym: FP7-ICT

Subprogramme Area: Personal health systems for monitoring and point-of-care diagnostics

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

AI-Powered CRISPR could Lead to Faster G…

Stanford Medicine researchers have developed an artificial intelligence (AI) tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing “copilot” supported by AI to help...

Groundbreaking AI Aims to Speed Lifesavi…

To solve a problem, we have to see it clearly. Whether it’s an infection by a novel virus or memory-stealing plaques forming in the brains of Alzheimer’s patients, visualizing disease processes...

AI Spots Hidden Signs of Depression in S…

Depression is one of the most common mental health challenges, but its early signs are often overlooked. It is often linked to reduced facial expressivity. However, whether mild depression or...

ChatGPT 4o Therapeutic Chatbot 'Ama…

One of the first randomized controlled trials assessing the effectiveness of a large language model (LLM) chatbot 'Amanda' for relationship support shows that a single session of chatbot therapy...

AI Tools Help Predict Severe Asthma Risk…

Mayo Clinic researchers have developed artificial intelligence (AI) tools that help identify which children with asthma face the highest risk of serious asthma exacerbation and acute respiratory infections. The study...

AI Model Forecasts Disease Risk Decades …

Imagine a future where your medical history could help predict what health conditions you might face in the next two decades. Researchers have developed a generative AI model that uses...

AI Model Indicates Four out of Ten Breas…

A project at Lund University in Sweden has trained an AI model to identify breast cancer patients who could be spared from axillary surgery. The model analyses previously unutilised information...

AI Distinguishes Glioblastoma from Look-…

A Harvard Medical School–led research team has developed an AI tool that can reliably tell apart two look-alike cancers found in the brain but with different origins, behaviors, and treatments. The...

Overcoming the AI Applicability Crisis a…

Opinion Article by Harry Lykostratis, Chief Executive, Open Medical. The government’s 10 Year Health Plan makes a lot of the potential of AI-software to support clinical decision making, improve productivity, and...

Smart Device Uses AI and Bioelectronics …

As a wound heals, it goes through several stages: clotting to stop bleeding, immune system response, scabbing, and scarring. A wearable device called "a-Heal," designed by engineers at the University...

Dartford and Gravesham Implements Clinis…

Dartford and Gravesham NHS Trust has taken a significant step towards a more digital future by rolling out electronic test ordering using Clinisys ICE. The trust deployed the order communications...